Background
==========

Aneuploidy is a common feature of cancer. Genetic alterations such as amplification, deletion, translocation and rearrangement could result in either gain-of-function or loss-of-function mutations in genes that modulate aspects of cell proliferation, differentiation, motility and survival. Whereas cytogenetic profiling techniques, such as comparative genomic hybridization (CGH) \[[@B1]\], have been useful in finding genetic abnormalities, other experimental approaches are frequently used to identify which specific gene(s) drive selection for the genetic aberration and contribute most to tumor progression. Common gene identification techniques include determining if a candidate gene contains a sequence mutation and/or determining if the candidate gene or gene product is abnormally expressed. As mutation analysis and protein expression studies are time-consuming, increasingly high-throughput gene-expression profiling is being used to identify abnormally expressed genes within a region of cytogenetic change \[[@B2],[@B3],[@B4],[@B5],[@B6]\].

Recently, several groups have observed that chromosomal changes can lead to regional biases in gene-expression values both in yeast (*Saccharomyces cerevisiae*) and in human tumors and tumor-derived cell lines \[[@B2],[@B3],[@B7],[@B8]\]. These studies suggest that a fraction of gene-expression values (15-25%) are regulated in concordance with gene dosage. A computational technique termed comparative genomic microarray analysis (CGMA) has previously been used to identify regions of allelic imbalance indirectly from gene-expression profiles of human tumors \[[@B8]\]. CGMA predicts chromosomal amplifications and deletions by organizing gene-expression data by genomic mapping location and scanning for regions that contain a statistically significant number of gene-expression values that change in the same relative direction. In this study, we apply CGMA analysis to a large hepatocellular carcinoma microarray dataset to demonstrate its validity as an alternative to CGH and to identify candidate genes in regions of frequent cytogenetic change.

Primary liver cancer in adults is the sixth most common form of cancer and the fourth leading cause of death from cancer worldwide \[[@B9],[@B10]\]. Through the examination of hepatitis B virus (HBV) - and hepatitis C virus (HCV)-induced tumors, two landmark CGH studies have suggested that a subset of cytogenetic changes frequently occurs in HCC \[[@B11],[@B12]\]. These include frequent gain of chromosomes 1q, 6p, 8q, 17q and 20q and frequent loss of chromosomes 1p, 4q, 6q, 8p, 13, 16 and 17p \[[@B11],[@B12]\]. In particular, gain of chromosomes 1q and 8q has been associated with the early development of HCC \[[@B12]\], whereas loss of chromosome 4q has been linked to increased aggressiveness of established tumors \[[@B11]\]. To determine whether gene-expression data could be used to identify cytogenetic changes accurately, we applied CGMA to a microarray dataset of HCC tumors and compared the CGMA predictions to existing CGH data. For HCC, CGMA was able to predict nearly all chromosomal aberrations identified previously by CGH. In addition, from the gene-expression data we also identified a set of genes whose expression values change most within the regions of cytogenetic change. These genes may represent candidate genes whose expression changes drive selection for chromosomal gains or losses.

Results
=======

CGMA predictions of cytogenetic changes
---------------------------------------

Normalized, log-transformed gene-expression data from 104 HCC gene-expression arrays \[[@B13]\] were obtained from the Stanford Microarray Database \[[@B14]\]. As CGMA analysis yields more intuitive predictions if the tumor expression data is compared to a normal tissue reference, the original HCC gene-expression data was mathematically transformed such that the pooled cell-line reference was replaced by a normal tissue reference (\[[@B3]\], see Materials and methods). Using this transformation, gene-expression values from the tumor sample are compared to corresponding values from non-cancerous tissue. Genomic regions that contain a disproportionate number of genes that change expression in the same relative direction (that is, show a gene-expression bias) may indicate an underlying chromosomal gain or loss (Figure [1a](#F1){ref-type="fig"}) \[[@B2],[@B3],[@B7],[@B8]\]. Chromosomal regions that contained a gene-expression bias with at least 95% confidence (a sign test *z*-statistic of at least 1.96, see Materials and methods) were identified for all 104 HCC expression profiles (Figure [1b](#F1){ref-type="fig"}). In addition, genomic regions that contained significant gene-expression biases in at least 35% of non-replicate samples were identified (Figure [1c](#F1){ref-type="fig"}). A 35% threshold was chosen because in previous CGMA profiling experiments this threshold yielded the highest CGMA to CGH agreement (\[[@B8]\] and data not shown). CGMA predicted frequent gains for chromosome 1q (gained in 72% of tumor samples), 6p (56%), 8q (49%), 17q (46%), 20q (46%), 5q (42%), 19P (37%) and 12q (35%). Frequent chromosomal losses were predicted for chromosome 4q (lost in 66% of tumor samples), 17p (48%), 13 (39%), 16 (37%), and 8p (35%). To determine if CGMA predictions were consistent with other cytogenetic profiling studies, the CGMA data were compared with data from two of the largest CGH profiling studies (67 and 50 samples, respectively) using HCC tumors \[[@B11],[@B12]\]. Of the 13 regions detected by CGMA, 10 (77%) were also implicated by CGH (Figure [1c](#F1){ref-type="fig"}). CGMA also detected three gained regions, chromosomes 5q, 12q and 19p, which were not implicated in the CGH analysis. CGMA failed to discover two regions of loss detected by CGH - chromosomes 1p and 6q. It is noteworthy that these particular losses were not identified in both CGH studies. These data suggest that CGMA predictions produce results very similar to traditional CGH profiling studies.

Comparison to previous HCC studies
----------------------------------

To date there have been at least 20 reports on the application of CGH to HCC \[[@B11],[@B12],[@B15],[@B16],[@B17],[@B18],[@B19],[@B20],[@B21],[@B22],[@B23],[@B24],[@B25],[@B26],[@B27],[@B28],[@B29],[@B30],[@B31],[@B32]\]. To determine whether the differences between the CGMA predictions and the two large CGH studies were similar to the experimental variation observed between different HCC CGH studies, predictions produced by CGMA were compared to 13 different HCC CGH profiling studies (Figure [2](#F2){ref-type="fig"}). CGMA produced 10 of 13 (77%) predictions that matched a consensus chromosomal aberration profile. On average, each CGH study matched the consensus profile in 78 ± 14% of the chromosomal regions analyzed. Therefore, the variation in CGMA results was similar to the variations between independent CGH studies. These results suggest that CGMA profiling is able to predict regions of frequent chromosomal imbalance in HCC as well as CGH profiling. As only 4 of the 104 (4%) samples analyzed scored positive for HCV infection, we could not use this dataset to detect significant cytogenetic differences between HCV-infected verses HBV-infected individuals (data not shown).

CGMA predictions of multifocal tumors
-------------------------------------

Included in the set of HCC gene-expression profiles were several cases in which multiple tumor nodules were removed from the same patient. In some cases the nodules had related gene-expression profiles (patients HK63, HK64, HK66) whereas in other cases tumors from the same patient had distinctive profiles (HK65, HK67, HK85) \[[@B33]\]. In particular, in patient HK67 the gene-expression profile from nodule HK67.1 was distinct from the expression profiles from nodules HK67.2 and HK67.3 \[[@B33]\]. Array CGH was used previously to determine the cytogenetic profiles of the tumor nodules from this patient \[[@B33]\]. Array CGH identified common cytogenetic abnormalities in patient HK67\'s tumors, including loss of chromosome 15q, an unusual gain of chromosome 19q, and loss of the centromeric region of chromosome 22. However, additional cytogenetic changes were found in tumors HK67.2 and HK67.3 that were not present in HK67.1. The cytogenetic profiling data coupled with the observation that HK67.2 and HK67.3 were both smaller in size and had an increased mitotic index, suggested that HK67.1 was the primary tumor and HK67.2 and HK67.3 were divergent HK67.1 subclones. To determine whether CGMA predictions agree with this monoclonal origin hypothesis, CGMA profiles of patient HK67\'s tumor nodules were isolated and organized by hierarchical clustering (Figure [3](#F3){ref-type="fig"}). CGMA also detected the common chromosome 19q gain and chromosome 15q loss in the HK67 tumors. CGMA did not identify a common loss on chromosome 22, however, CGMA identified other genetic aberrations (+8q, -16q and -19q) consistently found in the HK67 tumors. CGMA also identified additional aberrations (+2q, +5q, +12q) present in H67.2 and H67.3 that were not found in H67.1. Taken together, the CGMA data supports the hypothesis that the H67.2 and HK67.3 tumor nodules probably arose from HK67.1, but that additional distinct cytogenetic events had occurred in these nodules during tumor progression. In contrast, tumor nodules from patient HK64 have very similar gene-expression profiles and very similar cytogenetic profiles as predicted by CGMA, suggesting that these tumors have common origins and these nodules have not diverged significantly from the original lineage. In addition, tumor nodules from patient HK85 showed distinctive expression profiles and distinct HBV integration sites \[[@B33]\]. Similarly, the tumors from patient HK85 also show distinct CGMA-predicted cytogenetic profiles, reflecting the independent transforming mechanism (Figure [3](#F3){ref-type="fig"}).

Identification of candidate genes in regions of frequent cytogenetic change
---------------------------------------------------------------------------

Frequent cytogenetic abnormalities suggest that tumor-modifying genes (oncogenes or tumor suppressors) may be driving selection for the amplification or deletion of these particular genetic regions \[[@B6],[@B11],[@B12],[@B34],[@B35],[@B36]\]. An advantage of using CGMA profiling rather than traditional molecular genetic profiling is that access to gene-expression data is inherent in the analysis. CGMA allows cytogenetic analysis and the candidate gene approach to be performed with the same dataset. For example, the *c-myc* oncogene has been postulated to drive selection for frequent chromosome 8q amplification. Though *c-myc* is located on a region that both CGMA and CGH identify as frequently gained, c-*myc*\'s expression is increased more than twofold in less than 6% of the samples. In fact, in 52% of the HCC tissue samples, c-*myc*\'s expression is downregulated (Table [1](#T1){ref-type="table"}). This implies that increased *c-myc* expression is not driving the selection for the amplification of chromosomal region 8q in these samples. In the small region of chromosome 8q presented in Table [1](#T1){ref-type="table"}, two other genes (for squalene monooxygenase and pro2000) do show increased expression in a majority of HCC samples. Consistent with previous reports examining gene-expression levels in regions of cytogenetic change, expression levels for a large percentage of genes in this amplified region remain unchanged \[[@B3],[@B5],[@B8]\].

The set of genes that are consistently misregulated in regions of frequent cytogenetic change as predicted by CGMA are shown in Table [2](#T2){ref-type="table"}. Platelet-derived growth factor receptor alpha is consistently downregulated in a region of frequent cytogenetic loss and this suggests that loss of a member of this receptor gene family is important in HCC progression. It has previously been reported that a transcript (*PRLTS*) with sequence similarity to the extracellular domain of platelet-derived growth factor receptor may also be a tumor suppressor for HCC \[[@B35]\]. In addition, consistently increased expression of the pituitary tumor transforming gene 1 oncogene (*PTTG*) is observed in these samples (Table [2](#T2){ref-type="table"}). *PTTG* maps to chromosome 5q, a region that was identified as frequently changed by CGMA, but not identified in the majority of CGH profiling studies. *PTTP* overexpression in NIH 3T3 cells induces these cells to form tumors when injected into nude mice. Overexpression of this gene may result from frequent chromosomal amplification and may participate in HCC tumor progression.

CGMA prediction software
------------------------

To assist in identifying regions of unidirectional gene-expression bias, we have constructed a web-based program that processes two-color gene-expression data and identifies genomic regions that contain gene-expression biases. The input for this program is a simple tab-delimited gene-expression matrix file consisting of columns for the probe sequence identifier, probe name, and gene-expression ratios. Because different microarray technologies use different identifiers to describe the microarray probe, the program translates probe sequence identifiers (ids) such as GenBank accession numbers and UniGene cluster ids to Ensembl transcript ids using precompiled sequence comparisons. After data analysis, a summary table is displayed showing chromosomal regions that show significant (α ≤ 0.05) unidirectional gene-expression bias highlighted in either red or green, indicating either increased or decreased expression biases, respectively. The program can also send several output files to the user via e-mail. These files include a summary report that contains the *z*-statistic for each chromosomal region (positive for upregulated regions and negative for downregulated regions) and a list of genes located in regions of frequent cytogenetic change. The program is available at \[[@B37]\].

Discussion
==========

In this study we have used gene-expression profiling data to predict cytogenetic changes that frequently occur in HCC. Two landmark CGH analyses identified 12 different regions of frequent imbalance. However, one study found 8 regions and the other study found 11 \[[@B11],[@B12]\]. Five of these 12 regions were not found in both experiments. CGMA successfully identified 10 of 12 regions previously distinguished by CGH. CGMA also detected three regions that have not been implicated by these CGH studies. On average however, 22% of genomic regions indentified in a particular HCC CGH study are not constantly identified in other studies. Therefore, the three inconsistent CGMA predictions (3 of 13; 23%) are comparable to the inconsistencies between independent CGH studies for HCC.

Three additional regions were identified by CGMA that were not identified by CGH. While these CGMA-predicted regions were near the 35% cutoff for detection, they could represent other regions of allelic imbalance yet to be detected by CGH. It is also possible that biological mechanisms other than cytogenetic change could influence expression in large genomic regions and produce regional gene-expression biases. Additional molecular genetic work will be required to resolve these differences.

If CGH data are not available for a particular cancer type, but gene-expression profiling data are, then CGMA could allow rapid prediction of the cytogenetic abnormalities that frequently occur within that cancer type. Moreover, in instances where gene-expression profiling reveals previously unrecognized cancer subtypes, CGMA could determine whether cytogenetic differences are responsible for these different subtypes. In cancer types where traditional cytogenetic profiling has already been carried out, CGMA predictions could serve to confirm existing cytogenetic profiling data and be used further to examine candidate genes whose expression changes most within a region of frequent cytogenetic change. In this way CGMA can be combined with the candidate gene approach to identify genes that are directly involved in tumor progression.

Conclusions
===========

CGMA can be used to indicate chromosomal imbalances by detecting chromosomal regions that contain a disproportionate number of gene-expression values that change in the same relative direction. This analysis provides good evidence that CGMA is a practical alternative to CGH cytogenetic profiling when gene-expression profiling data is available.

Materials and methods
=====================

Normalization and filtering
---------------------------

Normalized, log-transformed gene-expression data for 104 HCC samples and 76 corresponding non-cancerous liver gene-expression profiles \[[@B13]\] were obtained from the Stanford Microarray Database \[[@B14]\]. Genes that were present in at least 75% of samples (10,037 genes) were used for further analysis. In this study, both the tumor samples and normal tissue samples were compared to a pooled cell-line reference \[[@B3]\]. To allow comparison of tumor gene-expression values to gene-expression values from surrounding non-cancerous tissue, new gene expression ratios, tumor verse normal (T/N), were estimated. To create the new ratios, log-transformed non-cancerous tissue ratios (N/U) were subtracted from the log-transformed HCC tissue ratios (T/U) for each gene such that log~2~(T/N) = log~2~(T/U) - log~2~(N/U). If an HCC sample did not have a corresponding non-cancerous sample, the global mean of the non-cancerous tissue gene-expression ratios were used.

CGMA analysis
-------------

To identify regional gene-expression biases, gene-expression values that map within a given chromosomal arm were collected and a sign test for a one-sample mean/median was used to determine whether a significant upward or downward bias was present in the expression values. An exception was made for chromosomes 13-16, 21 and 22. These chromosomes are more telocentric and therefore only their q-arms were tested for expression biases. Sequence comparisons were used to map microarray probe sequences (the sequences that are placed on the microarray) to predicted Ensembl transcripts (Ensembl version 6.28) \[[@B8]\]. Included in the Ensembl transcript annotations are chromosomal mapping locations at base-pair resolution. Redundancy introduced by replicate probes on the array and/or multiple probes mapping to the same gene were eliminated by averaging expression values that map to identical transcripts. Of the filtered set of 10,037 genes, 6,274 genes (63%) were unique and had associated genomic mapping information.

A sign test for the one-sample mean/median was used to determine whether a significant number of genes that map to a given chromosomal region change in a unidirectional manner. The algorithm scores a gene as up (+) or down (-) regulated if the magnitude of the expression value change is at least 1.8-fold. The sign test computes the probability, in the form of a *z*-statistic, of finding *x* upregulated genes out of *n* genes that change in a given genomic region. For simplicity, the *z*-statistic is computed using the normal approximation to the binomial distribution such that *z* = (2*x* - *n*)/sqrt(*n*). Genomic regions that contained less than 15 changed gene-expression values were excluded from further analysis. On average, 160 gene-expression values were located to each genomic region. The sign test *z*-statistic can be converted to a significance value (α) based on the two-tailed *z*-statistic (*z*~α/2~) critical values. For example, if *z* = 1.96, then α = 0.05; if *z* = 2.58 then α = 0.01, and so on.
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![Comparative genomic microarray analysis of hepatocellular carcinoma gene expression profiles. **(a)** A bar graph of log-transformed expression ratios (tumor versus normal) for genes located on chromosome 8q for sample SF13. The gene-expression values are organized from the chromosome telomere (top) to the centromere (bottom). A scale is shown above the graph. **(b)** CGMA expression profiles for 104 HCC tissue samples. Before CGMA analysis, gene-expression ratios were transformed such that each tumor gene-expression value was compared to the expression value from the non-cancerous tissue sample retrieved from the same patient. If the normal tissue was not present, the global mean of the non-tumor tissues was used. Genomic regions that show a significant number of downregulated genes are shown in green whereas genomic regions that show a significant number of upregulated genes are shown in red. The color intensity indicates the significance of the expression bias. The lowest-intensity color indicates a *z*-statistic = 1.96 (α = 0.05) while the most intense color indicates a *z*-statistic \<3.29 (α \< 0.001). The mean *z*-statistic for each genomic region is displayed in the rightmost column. **(c)** Chromosomal regions that had a significant gene-expression bias in more than 35% of HCC samples are listed. Red represents chromosomal gains and green represents losses. The corresponding percentages of samples that displayed frequent chromosomal aberrations identified in two CGH studies. Values from Wong *et al.*\[[@B12]\] are represented as CGH~1~ and values from Marchio *et al*. \[[@B11]\] are represented as CGH~2~.](gb-2002-3-12-research0075-1){#F1}

![Thirteen hepatocellular carcinoma CGH studies compared to CGMA predictions. Frequent chromosomal aberrations detected by 13 CGH studies (see References) and by CGMA are displayed as a heat map. Green indicates regions of frequent chromosomal loss and red indicates regions of frequent chromosomal gain. At the right is a consensus profile of chromosomal regions that were altered in at least 35% of the CGH studies.](gb-2002-3-12-research0075-2){#F2}

![CGMA comparisons of multiple tumor nodules isolated from the same patient. The data were generated and presented as in Figure [1](#F1){ref-type="fig"}. Tumor sample names are presented as patient number with a tumor nodule suffix. CGMA profiles were arranged by hierarchical clustering (average linkage clustering) using the sign test *z*-statistic of each chromosomal region \[[@B38]\].](gb-2002-3-12-research0075-3){#F3}

###### 

Identification of HCC candidate genes located within a region of chromosome 8q

  Transcript ID     Locus    Description                                             CGMA\*   Measured^†^   Changed^‡^
  ----------------- -------- ------------------------------------------------------- -------- ------------- ------------
  ENST00000276699   8q:127   Unknown (protein for mgc:14128)                         \+       \+            
  ENST00000276704   8q:127   cDNA flj14825 fis, clone ovarc1000781                   \+       \+            
  ENST00000297857   8q:127   Zinc finger homeobox protein zhx1 (zhx1 protein)        \+                     
  ENST00000287395   8q:127   Pro2000                                                 \+       \+            \+
  ENST00000287394   8q:127   Similar to riken cDNA 2610509g12 gene                   \+                     
  ENST00000287387   8q:127   Hypothetical 23.7 kDa protein                           \+                     
  ENST00000287396   8q:127   Similar to *Homo sapiens* F-box protein fbx25 (fbx25)   \+                     
  ENST00000262219   8q:127   Annexin a13 (annexin XIII)                              \+       \+            
  ENST00000303616   8q:128   \+                                                                             
  ENST00000287400   8q:128   \+                                                      \+                     
  ENST00000297861   8q:128   \+                                                                             
  ENST00000287402   8q:128   \+                                                                             
  ENST00000297632   8q:128   \+                                                                             
  ENST00000297630   8q:128   cDNA FLJ20772 FIS, Clone COL06053                       \+                     
  ENST00000303545   8q:128   \+                                                                             
  ENST00000276692   8q:128   Cda11                                                   \+                     
  ENST00000276689   8q:128   NADH-ubiquinone oxidoreductase b22 subunit              \+                     
  ENST00000287414   8q:128   Hypothetical protein kiaa0429                           \+       \+            
  ENST00000265896   8q:129   Squalene monooxygenase                                  \+       \+            \+
  ENST00000303443   8q:129                                                           \+                     
  ENST00000265897   8q:129                                                           \+       \+            
  ENST00000297614   8q:129   \+                                                                             
  ENST00000287437   8q:129   cDNA flj32440 fis, clone skmus2001492                   \+                     
  ENST00000297644   8q:129   G-protein-coupled receptor induced protein Gig2         \+                     
  ENST00000259534   8q:129   Contains a reverse transcriptase domain                 \+                     
  ENST00000297628   8q:130   \+                                                                             
  ENST00000305022   8q:130   \+                                                                             
  ENST00000297624   8q:130   \+                                                                             
  ENST00000305005   8q:130   \+                                                                             
  ENST00000287390   8q:130   Estradiol 17 beta dehydrogenase 4 EC 1.1.1              \+                     
  ENST00000297858   8q:130   Hypothetical 23.7 kDa protein                           \+                     
  ENST00000287393   8q:130   \+                                                                             
  ENST00000297860   8q:130   \+                                                                             
  ENST00000304916   8q:131   \+                                                                             
  ENST00000304908   8q:132   \+                                                                             
  ENST00000259523   8q:132   Myc proto-oncogene protein (c-Myc)                      \+       \+            \-
  ENST00000297727   8q:132   Contains a reverse transcriptase domain                 \+                     

\*Region of frequent CGMA-predicted cytogenetic change (+). ^†^Expression was measured in the microarray experiment (+). ^‡^Expression increased (+) or decreased (-) at least twofold in at least 50% of tumor samples.

###### 

Misregulated genes located in regions of frequent cytogenetic aberrations

  Ensembl ID\*      Locus     Name                                                         Fold change^†^
  ----------------- --------- ------------------------------------------------------------ ----------------
  ENST00000271452   1q:165    Hypothetical protein NUF2R                                   10.4
  ENST00000243893   20q:44    Ubiquitin-conjugating enzyme E2C                             8.5
  ENST00000216918   20q:30    Chromosome 20 open reading frame 1                           7.2
  ENST00000257535   5q:160    Pituitary tumor-transforming 1                               6.7
  ENST00000171466   1q:209    HSPC150 protein similar to ubiquitin-conjugating enzyme      5.6
  ENST00000287395   8q:122    PRO2000 protein                                              4.7
  ENST00000256686   12q:49    Hypothetical protein MGC5576                                 4.6
  ENST00000229922   6p:18     Adenylyl cyclase-associated protein 2                        4.6
  ENST00000289943   1q:163    Ribonucleotide reductase M2 polypeptide                      4.5
  ENST00000271474   1q:165    Regulator of G-protein signalling 5                          4.1
  ENST00000230056   6p:22     Geminin                                                      3.7
  ENST00000263041   6p:56     Glutathione S-transferase A4                                 3.5
  ENST00000245561   1q:156    Chromosome 1 open reading frame 2                            3.4
  ENST00000280896   4q:98     Alcohol dehydrogenase 4 (class II), pi polypeptide           -42
  ENST00000245182   16q:57    Metallothionein 1L                                           -33
  ENST00000225383   17q:64    RNA helicase-related protein                                 -25
  ENST00000257600   12q:105   deltex (*Drosophila*) homolog 1                              -16.9
  ENST00000239938   5q:140    Early growth response 1                                      -10
  ENST00000271629   1q:152    Extracellular matrix protein 1                               -9.6
  ENST00000292494   8q:142    Lymphocyte antigen 6 complex, locus E                        -9.4
  ENST00000283088   8p:1      KIAA0711 gene product                                        -7.7
  ENST00000250080   17p:8     Sex hormone-binding globulin                                 -7
  ENST00000266671   12q:76    Pleckstrin homology-like domain, family A, member 1          -7
  ENST00000264005   16q:68    Lecithin-cholesterol acyltransferase                         -6.7
  ENST00000280188   4q:175    Glycoprotein M6A                                             -6.6
  ENST00000262767   17q:80    Baculoviral IAP repeat-containing 5 (survivin)               -6.6
  ENST00000225831   17q:32    Small inducible cytokine A2                                  -5.9
  ENST00000257290   4q:55     Platelet-derived growth factor receptor, alpha polypeptide   -5.2
  ENST00000273912   4q:83     Hypothetical protein                                         -5.2
  ENST00000219302   16q:2     Non-metastatic cells 3, protein expressed in                 -5
  ENST00000255389   17q:22    Phosphatidylethanolamine N-methyltransferase                 -4.9
  ENST00000218564   13q:95    Dopachrome tautomerase                                       -4.8
  ENST00000219163   16q:20    KIAA1504 protein                                             -3.7
  ENST00000253557   17q:31    Cyclin-dependent kinase 5, regulatory subunit 1 (p35)        -3.6

\*Genes whose expression changed at least twofold in 70% of tumor samples in the same relative direction as the cytogenetic change and are located in regions identified as cytogenetically abnomal by CGMA in at least 35% of samples. ^†^Fold difference in tumor tissue gene expression relative to non-cancerous tissue.
